Detection of circulating tumor cells in prostate cancer patients: Methodological pitfalls and clinical relevance

Molecular Medicine

Volumn 15, Issue 3-4, 2009, Pages 101-114

  Panteleakou, Zacharoula ^a   Lembessis, Peter ^a,b   Sourla, Antigone ^a,b   Pissimissis, Nikolaos ^a   Polyzos, Aristides ^a   Deliveliotis, Charalambos ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Diagnostic and Therapeutic Medical Center   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; PARATHYROID HORMONE RELATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PSCA PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

BLOOD ANALYSIS; BODY FLUID; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CELL ISOLATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; DISSEMINATED CANCER; HUMAN; INTERMETHOD COMPARISON; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; TUMOR CELL; BLOOD; CYTOLOGY; GENETICS; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; STANDARD; TUMOR EMBOLISM;

ANTIGENS, SURFACE; BODY FLUIDS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KERATIN-19; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PARATHYROID HORMONE-RELATED PROTEIN; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 64549101978     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2008.00116     Document Type: Review

References (193)

1. Landis SH, Murray T, Bolden S, Wingo PA. (1999) Cancer statistics, 1999. CA Cancer J. Clin. 49:8-31.
2. Coffey DS. (1993) Prostate cancer: an overview of an increasing dilemma. Cancer 71:880-6.
3. Arya M, et al. (2006) The metastatic cascade in prostate cancer. Surg. Oncol. 15:117-28.
4. Pantel K, Brakenhoff RH. (2004) Dissecting the metastatic cascade. Nat. Rev. Cancer 4:448-56.
5. Weiss L. (2000) Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19:193-383.
6. Jacob K, Sollier C, Jabado N. (2007) Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev. Proteomics 4:741-56.
7. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. (2008) Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 22:341-55.
8. Jacobs SC. (1983) Spread of prostatic cancer to bone. Urology 21:337-44.
9. Bubendorf L, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31:578-83.
10. Labrie F, et al. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med. 16:425-39.
11. Glaves D. (1983) Correlation between circulating cancer cells and incidence of metastases. Br. J. Cancer 48:665-73.
12. Mocellin S, Keilholz U, Rossi CR, Nitti D. (2006) Circulating tumor cells: the "leukemic phase" of solid cancers. Trends Mol. Med. 12:130-9.
13. Poste G, Fidler IJ. (1980) The pathogenesis of cancer metastasis. Nature 283:139-46.
14. Koutsilieris M. (1995) Skeletal metastases in advanced prostate cancer: cell biology and therapy.Crit. Rev. Oncol. Hematol. 18:51-64.
15. Kim HR, Lin HM, Biliran H, Raz A. (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 59:4148-54.
16. Yang J, Mani SA, Weinberg RA. (2006) Exploring a new twist on tumor metastasis. Cancer Res. 66:4549-52.
17. Thompson EW, Newgreen DF, Tarin D. (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 65:5991-5; discussion 5995.
18. Bates RC, Mercurio AM. (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol. Ther. 4:365-70.
19. Willipinski-Stapelfeldt B, et al. (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human mi-crometastatic and primary breast carcinoma cells. Clin. Cancer Res. 11:8006-14.
20. Lang SH, et al. (2002) Enhanced expression of vi-mentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52:253-63.
21. Arias AM. (2001) Epithelial mesenchymal interactions in cancer and development. Cell 105:425-31.
22. Christiansen JJ, Rajasekaran AK. (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66:8319-26.
23. Tarin D, Thompson EW, Newgreen DF. (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65:5996-6000; discussion 6000-1.
24. Rubin MA, et al. (2000) Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6:1038-45.
25. Christiansen JJ, et al. (2005) N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol. Cancer Ther. 4:704-14.
26. Koutsilieris M, et al. (2001) A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J. Clin. Endocrinol. Metab 86:5729-36.
27. Fidler IJ. (2003) The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. Cancer 3:453-8.
28. Karamanolakis D, et al. (2002) Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Mol. Med. 8:667-75.
29. Koutsilieris M. (1993) Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. 13:443-9.
30. Mitsiades CS, Koutsilieris M. (2001) Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin. Investig. Drugs 10:1099-15.
31. Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M. (2005) Prostate cancer cell survival pathways activated by bone metastasis mi-croenvironment. J. Musculoskelet. Neuronal Interact. 5:135-44.
32. Weiss L. (1990) Metastatic inefficiency. Adv. Cancer Res. 54:159-211.
33. Sugarbaker PH. (1993) Metastatic inefficiency: the scientific basis for resection of liver metas-tases from colorectal cancer. J. Surg. Oncol. Suppl. 3:158-60.
34. Fidler IJ. (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 50:6130-8.
35. Fidler IJ, Kripke ML. (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-5.
36. Fidler IJ. (1970) Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl. Cancer Inst. 45:773-82.
37. Liotta LA, Saidel MG, Kleinerman J. (1976) The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 36:889-94.
38. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-11.
39. Martinez-Climent JA, Andreu EJ, Prosper F. (2006) Somatic stem cells and the origin of cancer. Clin. Transl Oncol. 8:647-63.
40. Jabbour MN, Matioli GT. (2006) Age dependent and cellular origin (stem versus progenitor) of a selected group of spontaneous brain tumors in humans. Med. Hypotheses 67:1437-42.
41. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. (2005) Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 73:463-73.
42. Alix-Panabieres C, et al. (2005) Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods 299:177-88.
43. Alix-Panabieres C, et al. (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 53:537-9.
44. Oh WK, Kantoff PW. (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 160:1220-9.
45. Mukamel E, Hanna J, deKernion JB. (1987) Pitfalls in preoperative staging in prostate cancer. Urology30:318-21.
46. Makarovskiy AN, et al. (1997) Application of im-munomagnetic beads in combination with RT- PCR for the detection of circulating prostate cancer cells. J. Clin. Lab. Anal. 11:346-50.
47. Morgan TM, Lange PH, Vessella RL. (2007) Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci. 12:3000-9.
48. Zheng S, et al. (2007) Membrane microfilter device for selective capture, electrolysis and ge-nomic analysis of human circulating tumor cells. J. Chromatogr. A. 1162:154-61.
49. Kruger W, et al. (2000) Immunomagnetic tumor cell selection-implications for the detection of disseminated cancer cells. Transfusion 40:1489-1493.
50. Paterlini-Brechot P, Benali NL. (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253:180-204.
51. Zigeuner RE, Riesenberg R, Pohla H, Hofstetter A, Oberneder R. (2000) Immunomagnetic cell enrichment detects more disseminated cancer cells than immunocytochemistry in vitro. J. Urol. 164:1834-7.
52. Racila E, et al. (1998) Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. U. S. A. 95:4589-94.
53. Meye A, et al. (2002) Isolation and enrichment of urologic tumor cells in blood samples by a semi- automated CD45 depletion autoMACS protocol. Int. J. Oncol. 21:521-30.
54. Ghossein RA, et al. (1999) Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn. Mol. Pathol. 8:59-65.
55. Kong D, et al. (2008) Platelet-derived growth fac-tor-D overexpression contributes to epithelial- mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26:1425-35.
56. Loberg RD, et al. (2004) Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 6:302-9.
57. Ellis WJ, et al. (2003) Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 61:277-81.
58. Riethdorf S, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13:920-8.
59. Cristofanilli M, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351:781-91.
60. Davis JW, et al. (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol. 179:2187-91.
61. Borgono CA, Diamandis EP. (2004) The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4:876-90.
62. Li C, et al. (2005) Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. J. Am. Chem. Soc. 127:12484-5.
63. Crawford ED, Abrahamsson PA. (2008) PSA-
64. based screening for prostate cancer: how does it compare with other cancer screening tests? Eur. Urol. 54:262-73.
65. Papsidero LD, et al. (1981) Prostate antigen: a marker for human prostate epithelial cells. J. Natl. Cancer Inst. 66:37-42.
66. Elgamal AA, et al. (1996) Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J. Urol. 156:464-8.
67. Frazier HA, Humphrey PA, Burchette JL, Paulson DF. (1992) Immunoreactive prostatic specific antigen in male periurethral glands. J. Urol. 147:246-8.
68. Stenman UH, Leinonen J, Zhang WM, Finne P. (1999) Prostate-specific antigen. Semin. Cancer Biol. 9:83-93.
69. Black MH, Diamandis EP. (2000) The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res. Treat. 59:1-14.
70. Yu H, et al. (1995) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 55:2104-10.
71. Henttu P, Liao SS, Vihko P. (1992) Androgens upregulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down- regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 130:766-72.
72. Pampalakis G, Scorilas A, Sotiropoulou G. (2008) Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clin. Biochem. 41:591-7.
73. Riesenberg R, et al. (1993) Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 99:61-6.
74. Mueller P, et al. (1998) Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 83:538-46.
75. Israeli RS, Powell CT, Fair WR, Heston WD. (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53:227-30.
76. O′Keefe DS, et al. (1998) Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1443:113-27.
77. Pinto JT, et al. (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human pro-static carcinoma cells. Clin. Cancer Res. 2:1445-51.
78. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. (1998) Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther. 286:1020-5.
79. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. (1994) Expression of the prostate-specific membrane antigen. Cancer Res. 54:1807-11.
80. Fair WR, Israeli RS, Heston WD. (1997) Prostate-specific membrane antigen. Prostate 32:140-8.
81. Gregorakis AK, Holmes EH, Murphy GP. (1998) Prostate-specific membrane antigen: current and future utility. Semin. Urol. Oncol. 16:2-12.
82. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3:81-5.
83. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637-40.
84. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 55:1441-3.
85. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. (2003) Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int. J. Cancer 107:323-9.
86. Cao KY, et al. (2007) High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 67:1791-1800.
87. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neopla-sia and adenocarcinoma: a study of 184 cases. Cancer 82:2256-2261.+
88. Kawakami M, Nakayama J. (1997) Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57:2321-4.
89. Wright GL, et al. (1996) Upregulation of prostate-specific membrane antigen after andro-gen-deprivation therapy. Urology 48:326-34.
90. Ross JS, et al. (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 9:6357-62.
91. Reiter RE, et al. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 95:1735-40.
92. Visakorpi T, et al. (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55:342-7.
93. Sato K, et al. (1999) Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91:1574-80.
94. Van Den Berg C, et al. (1995) DNAsequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin. Cancer Res. 1:11-8.
95. Antica M, Wu L, Scollay R. (1997) Stem cell antigen 2 expression in adult and developing mice. Immunol Lett. 55:47-51.
96. Classon BJ, Coverdale L. (1994) Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc. Natl. Acad. Sci. U. S. A. 91:5296-300.
97. Gu Z, et al. (2000) Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19:1288-96.
98. Zhigang Z, Wenlv S. (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J. Surg. Oncol. 2:13.
99. Lam JS, et al. (2005) Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 11:2591-6.
100. Ross S, et al. (2002) Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62:2546-53.
101. Bartek J, et al. (1986) Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem. J. 18:565-75.
102. Datta YH, et al. (1994) Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J. Clin. Oncol.12:475-82.
103. Traweek ST, Liu J, Battifora H. (1993) Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am. J. Pathol. 142:1111-8.
104. Peck K, et al. (1998) Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res.58:2761-5.
105. Yeh KH, et al. (1998) Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)-possible clinical significance in advanced gastric cancer. Anticancer Res. 18:1283-6.
106. Aihara T, et al. (1997) Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. Int. J. Cancer 72:408-11.
107. Hoffmann K, et al. (2007) Detection of disseminated pancreatic cells by amplification of cytok-eratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J. Gastroenterol. 13:257-63.
108. Stathopoulou A, et al. (2003) Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9:5145-51.
109. Balducci E, et al. (2005) A new nested primer pair improves the specificity of CK-19 mRNA detection by RT-PCR in occult breast cancer cells. Int. J. Biol. Markers 20:28-33.
110. Ruud P, Fodstad O, Hovig E. (1999) Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int. J. Cancer 80:119-25.
111. Krismann M, et al. (1995) Low specificity of cytok-eratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J. Clin. Oncol. 13:2769-75.
112. Savtchenko ES, Schiff TA, Jiang CK, Freedberg IM, Blumenberg M. (1988) Embryonic expression of the human 40-kD keratin: evidence from a processed pseudogene sequence. Am. J. Hum. Genet. 43:630-7.
113. Jung R, et al. (1998) Specificity of reverse tran-scriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br. J. Cancer 78:1194-8.
114. Zieglschmid V, Hollmann C, Bocher O. (2005) Detection of disseminated tumor cells in peripheral blood. Crit. Rev. Clin. Lab. Sci. 42:155-96.
115. Suva LJ, et al. (1987) Aparathyroid hormone-related protein implicated in malignant hypercal- cemia: cloning and expression. Science 237:893-6.
116. Rankin W, Grill V, Martin TJ. (1997) Parathyroid hormone-related protein and hypercalcemia. Cancer 80:1564-71.
117. Abou-Samra AB, et al. (1992) Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intra-cellular free calcium. Proc. Natl. Acad. Sci. U. S. A.89:2732-6
118. .117. Juppner H, Hesch RD. (1991) Biochemical characterization of cellular hormone receptors. Curr. Top. Pathol 83:53-69.
119. Strewler GJ, et al. (1987) Parathyroid hormone like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J. Clin. Invest. 80:1803-7.
120. de Papp AE, Stewart AF. (1993) Parathyroid hormone-related protein a peptide of diverse physiologic functions. Trends Endocrinol. Metab. 4:181-7.
121. Rodda CP, et al. (1988) Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J. Endocrinol. 117:261-71.
122. 121. Southby J, O′Keeffe LM, Martin TJ, Gillespie MT. (1995) Alternative promoter usage and mRNA splicing pathways for parathyroid hormone-related protein in normal tissues and tumours. Br. J. Cancer 72:702-7.
123. Campos RV, Wang C, Drucker DJ. (1992) Regulation of parathyroid hormone-related peptide (PTHrP) gene transcription: cell- and tissue-specific promoter utilization mediated by multiple positive and negative cis-acting DNA elements. Mol. Endocrinol. 6:1642-52.
124. Iwamura M, et al. (1994) Parathyroid hormone-related protein is expressed by prostatic neu- roendocrine cells. Urology 43:667-74.
125. Kiriyama T, et al. (1993) Transforming growth factor beta stimulation of parathyroid hormone- related protein (PTHrP): a paracrine regulator? Mol. Cell. Endocrinol. 92:55-62.
126. Pirola CJ, et al. (1993) Angiotensin II regulates parathyroid hormone-related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. J. Biol. Chem. 268:1987-94.
127. Glatz JA, et al. (1994) Dexamethasone regulation of parathyroid hormone-related protein (PTHrP) expression in a squamous cancer cell line. Mol. Cell. Endocrinol. 101:295-306.
128. Asadi F, et al. (1996) Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign pro-static hyperplasia. Hum. Pathol. 27:1319-23.
129. Iwamura M, et al. (1994) Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43:675-9.
130. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. (1999) Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int. J. Cancer 80:257-64.
131. Deftos LJ. (2000) Prostate carcinoma: production of bioactive factors. Cancer 88:3002-8.
132. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. (2005) Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun. 327:468-72.
133. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW, George NJ. (2002) Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br. J. Cancer 86:322-5. 133. Downey SE, et al. (1997) Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J. Pathol. 183:212-217.
134. Ghossein RA, Bhattacharya S. (2000) Molecular
135. detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur. J. Cancer 36:1681-94.
136. Katz AE, et al. (1994) Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765-75.
137. Moreno JG, et al. (1992) Detection of hematoge-nous micrometastasis in patients with prostate cancer. Cancer Res. 52:6110-2.
138. Lembessis P, et al. (2007) Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin. Chem. Lab. Med. 45:1488-94.
139. Gomella LG, Raj GV, Moreno JG. (1997) Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J. Urol. 158:326-37.
140. Chelly J, Concordet JP, Kaplan JC, Kahn A. (1989) Illegitimate transcription: transcription of any gene in any cell type. Proc. Natl. Acad. Sci. U. S. A. 86:2617-21.
141. Fava TA, et al. (2001) Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 19:3951-9.
142. Ghossein RA, et al. (1995) Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol. 13:1195-200.
143. Israeli RS, et al. (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 54:6306-10.
144. Sokoloff MH, et al. (1996) Quantitative poly-merase chain reaction does not improve preoper-ative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J. Urol. 156:1560-6.
145. Gao CL, et al. (1999) Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology 53:714-21.
146. Gradilone A, et al. (2003) Detection of CK19,CK20 and EGFR mRNAs in peripheral blood of pression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun. 327:468-72.
147. Smith MR, Biggar S, Hussain M. (1995) Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res. 55:2640-4.
148. Henke W, et al. (1997) Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int. J. Cancer 70:52-6.
149. Gala JL, et al. (1998) Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin. Chem. 44:472-81.
150. Cama C, et al. (1995) Molecular staging of prostate cancer; II: a comparison of the application of an enhanced reverse transcriptase poly-merase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J. Urol. 153:1373-8.
151. Lintula S, Stenman UH. (1997) The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J. Urol. 157:1969-72.
152. Kaplan JC, Kahn A, Chelly J. (1992) Illegitimate transcription: its use in the study of inherited disease. Hum. Mutat. 1:357-60.
153. Eschwege P, et al. (1995) Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346:1528-30.
154. Oefelein MG, et al. (1996) Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J. Urol. 155:238-42.
155. Koutsilieris M, Lembessis P, Luu-The V, Sourla A. (1999) Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin. Exp. Metastasis 17:823-30.
156. Olsson CA, de Vries GM, Buttyan R, Katz AE. (1997) Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol. Clin. North Am. 24:367-78.
157. Hara N, et al. (2001) Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy. Br. J. Cancer 85:557-62.
158. Ellis WJ, et al. (1998) The value of a reverse tran- scriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J. Urol. 159:1134-8.
159. Dumas F, Eschwege P, Loric S. (1997) Acute bacterial prostatitis induces hematogenous dissemination of prostate epithelial cells. Clin. Chem. 43:2007-8.
160. McIntyre IG, et al. (2000) Optimization of the reerse transcriptase polymerase chain reaction for the detection of circulating prostate cells. Br. Cancer 83:992-7.
161. Berteau P, et al. (1998) Influence of blood storage and sample processing on molecular detection of circulating prostate cells in cancer. Clin. hem. 44:677-9.
162. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF. (2004) Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR. Clin. hem. 50:785-6.
163. Young CY, et al. (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line NCaP. Cancer Res. 51:3748-52.
164. Qiu SD, et al. (1990) In situ hybridization of rostate-specific antigen mRNA in human rostate. J. Urol. 144:1550-6.
165. Grasso YZ, Gupta MK, Levin HS, Zippe CD, lein EA. (1998) Combined nested RT-PCR ssay or prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. ancer Res. 58:1456-9.
166. Shariat SF, et al. (2003) Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 63:5874-8.
167. Shariat SF, et al. (2002) Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 62:5974-9. 67. Bianco FJ Jr, Powell IJ, Cher ML, Wood DP Jr. 2002) Presence of circulating prostate cancer cells in African American males adversely affects survival. Urol. Oncol. 7:147-52.
168. Kantoff PW, et al. (2001) Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J. Clin. Oncol. 19:3025-8.
169. Mejean A, et al. (2000) Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J. Urol. 163:2022-9.
170. Thiounn N, et al. (1997) Positive prostate- specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic mi-crometastases. Urology 50:245-50.
171. Martinez-Pineiro L, et al. (2003) Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur. Urol. 43:342-50.
172. Katz AE, et al. (1996) The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol. Clin North Am. 23:541-9.
173. Katz AE, et al. (1996) Molecular staging of genitourinary malignancies. Urology 47:948-58.
174. Olsson CA, et al. (1996) Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J. Urol. 155:1557-62.
175. Mitsiades CS, et al. (2004) Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin. Exp. Metastasis 21:495-505.
176. Sourla A, et al. (2001) Conversion of nested re-verse- transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res. 21:3565-70.
177. Olsson CA, et al. (1996) The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br. J. Urol. 77:411-7.
178. Ghossein RA, et al. (1997) Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50:100-5.
179. Okegawa T, et al. (1998) Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. Int. J. Urol. 5:349-56.
180. Zhang Y, Zippe CD, Van Lente F, Klein EA, Gupta MK. (1997) Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin. Cancer Res. 3:1215-20.
181. Loric S, et al. (1995) Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin. Chem. 41:1698-704.
182. Noguchi M, Miyajima J, Itoh K, Noda S. (1997) Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction. Int. J. Urol. 4:374-9.
183. Hara N, et al. (2002) Reverse transcription-poly-merase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin. Cancer Res. 8:1794-9.
184. Han KR, et al. (2004) Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 171:1117-21.
185. Joung JY, et al. (2007) Reverse transcriptase-polymerase chain reaction and immunohisto-chemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer. Int J. Urol. 14:635-3.
186. Dannull J, et al. (2000) Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 60:5522-8.
187. Zhigang Z, Wenlu S. (2005) Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 65:299-305.
188. Kahn HJ, et al. (2000) RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. Breast Cancer Res. Treat. 60:143-51.
189. Chen TF, et al. (2007) CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 56:105-14.
190. Stathopoulou A, et al. (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20:3404-12.
191. Xenidis N, et al. (2007) Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann. Oncol. 18:1623-31.
192. Kaneda T, et al. (1998) Detection of urogenital malignant cells in the peripheral blood by nested RT-PCR using keratin 19 mRNA [in Japanese]. Nippon Hinyokika Gakkai Zasshi 89:33-42.
193. Tobias-Machado M, et al. (2005) Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori 91:248-52.